{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-016064","form_type":"8-K","ticker":"MTNB","cik":"0001582554","company_name":"Matinas BioPharma Holdings, Inc.","filed_at":"2025-06-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.876188+00:00","generated_at":"2026-05-18T23:43:02.235962+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Stockholders approve reverse split up to 1:199, authorized shares to 500M, and new equity plan","bullets":["All five director nominees elected; advisory vote on executive compensation passes with 5.56M for, 0.11M against.","Reverse stock split authorized in range of 1-for-2 to 1-for-199 over two years; 6.94M for, 0.54M against.","Authorized common shares increased from 250M to 500M; 6.91M for, 0.57M against.","2025 Equity Incentive Plan approved with 5.39M for, 0.28M against, 1.81M broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-016064","json":"https://secwatch.observer/filing/0001641172-25-016064.json","markdown":"https://secwatch.observer/filing/0001641172-25-016064.md","text":"https://secwatch.observer/filing/0001641172-25-016064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1582554/000164117225016064/0001641172-25-016064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1582554/000164117225016064/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T23:43:02.235962+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}